Robert Spurr, U.S. President-Pharma Business at Bausch Health Companies Inc. (BHC), sold 1,595 shares at $23.37 ($37K) on 2022-03-02, disclosed to the SEC on 2022-03-04.
Scheduled sale ($37k) by U.S. President-Pharma Business under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BHC | SELL | 2022-02-17 | $163K | — | Filing → |
| BHC | SELL | 2022-01-20 | $173K | — | Filing → |